These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 37951998)

  • 1. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study.
    Congdon S; Narrowe Z; Yone N; Gunn J; Deng Y; Nori P; Cowman K; Islam M; Rikin S; Starrels J
    Sci Rep; 2023 Nov; 13(1):19688. PubMed ID: 37951998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
    Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
    Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.
    Wang H; Wei Y; Hung CT; Lin G; Jiang X; Li C; Jia KM; Yam CHK; Chow TY; Ho JY; Wang Y; Zhao S; Guo Z; Li K; Yang A; Mok CKP; Hui DSC; Yeoh EK; Chong KC
    Lancet Infect Dis; 2024 Oct; 24(10):1130-1140. PubMed ID: 38710190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.
    Low EV; Pathmanathan MD; Ten YY; Chidambaram SK; Kim WR; Lee WJ; Teh ZW; Appannan MR; Ismail M; Samad AA; Peariasamy KM
    BMC Infect Dis; 2024 Aug; 24(1):780. PubMed ID: 39103829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
    Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
    Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
    Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
    Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19.
    Schwartz KL; Wang J; Tadrous M; Langford BJ; Daneman N; Leung V; Gomes T; Friedman L; Daley P; Brown KA
    CMAJ; 2023 Feb; 195(6):E220-E226. PubMed ID: 36781188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
    J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
    Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
    Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
    Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.
    Xie Y; Choi T; Al-Aly Z
    JAMA Intern Med; 2023 Jun; 183(6):554-564. PubMed ID: 36951829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
    Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
    MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic.
    Bose-Brill S; Hirabayashi K; Schwimmer E; Pajor NM; Rao S; Mejias A; Jhaveri R; Forrest CB; Bailey LC; Christakis DA; Thacker D; Hanley PC; Patel PB; Cogen JD; Block JP; Prahalad P; Lorman V; Lee GM;
    Hosp Pediatr; 2024 Aug; 14(8):e341-e348. PubMed ID: 39076115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
    Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.